ALFA Finder| Revenue growth | 22% YoY in Q4FY26; 14.5% for FY26. |
|---|---|
| Margins | Q4 Adjusted EBITDA margin at 30%; targeting mid-teen EBITDA for Cenexi. |
| Order book | Current order book supports 12-13% FY27 growth guidance. |
| Demand visibility | Strong order book and forecast; high demand for new launches. |
| Management confidence | High confidence in sustaining momentum and mid-term growth targets. |
Growth
FY26 revenue grew 14.5% to INR 64,307M. US market grew 26% in Q4 and 11% for the full year.
Outlook
Guided 12-13% constant currency growth for FY27; INR 2,000Cr capex planned over next three years.
Risks
Supply chain issues in Middle East caused a 1-2% revenue impact; potential 5-6% cost increase in glass/vials.
Earnings Call filed with NSE, NSE: GLAND. Summary written with AI assistance from the document.
Gland Pharma Ltd: key numbers
- Share price
- ₹3,300.50
- Market cap
- ₹54,462 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 44.1×Sector 43.8×
- Promoter holding
- 45.75%-6.02% QoQ
- FII holding
- 10.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gland Pharma Ltd
All →Gland Pharma Annual General Meeting
Gland Pharma's shareholders approved the appointment of Xingli Wang as Non-Executive Non-Independent Director via postal ballot. The ordinary resolution passed with 97.07% of votes in favour.
Gland Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹18,336 Mn (+23% YoY), PAT ₹2,908 Mn (+58%), adj. EBITDA margin 27%. US CDMO and launches lead; India and RoW weak.
Gland Pharma Results Update
Gland Pharma reported Q2FY27 revenue of Rs. 18,336 Mn, up 23% YoY, and PAT of Rs. 2,908 Mn, up 58% YoY. The press release accompanies its quarterly financial results filing.
Gland Pharma Q2 FY27 Results: Net Profit ₹290.8 Cr, Up 58.3% YoY
Gland Pharma Ltd reported revenue from operations of ₹1,834 Cr (+23.3% YoY) and net profit of ₹290.8 Cr (+58.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹290.8 Cr · +58.3% YoY
Gland Pharma Regulatory Approval
Gland Pharma received USFDA approval for Methylprednisolone Acetate Injectable Suspension USP in multiple vial formats. The product is bioequivalent to Pfizer's Depo-Medrol in a ~$214M US market.
Gland Pharma Management Change
Gland Pharma appointed Ajay Sahni as CEO of its wholly-owned subsidiary Gland Pharma International Pte. Ltd, effective 2 November 2026. He will lead the Cenexi business.